Italy Ran an Innovation Test for Eight Years.
Italy graded new medicines full, conditional or not innovative for eight years. The 2025 reform abolished the middle grade, because almost nothing ever graduated.
AIFA
Reimbursement Series: CMS and Europe Reimbursement Pathway Accelerates Innovation
In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators … Read more
Reimbursement Series: Anchors Affordable Breakthroughs – AIFA and TLV Expand European Coverage
Sweden expands reimbursement decisions driving biotech access and patient impact.